Felix Huth

发表

Ribociclib Drug-Drug Interactions - Clinical Evaluations and PBPK Modeling to Guide Drug Labeling.

T. Heimbach, A. Chakraborty, Hilmar Schiller, 2020, Clinical pharmacology and therapeutics.

Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling

R. Woessner, A. Drollmann, Hilmar Schiller, 2021, Clinical and translational science.

Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions

T. Heimbach, Hilmar Schiller, K. Umehara, 2019, Drug metabolism and personalized therapy.

Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations

C. Germa, K. Umehara, S. Dhuria, 2017, Clinical pharmacology and therapeutics.

Examining P‐gp efflux kinetics guided by the BDDCS ‐ Rational selection of in vitro assay designs and mathematical models

G. Camenisch, Hilmar Schiller, K. Umehara, 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects

E. Legangneux, S. Neelakantham, Swati Dumitras, 2018, European Journal of Clinical Pharmacology.

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics

G. Camenisch, M. Ufer, Felix Huth, 2017, European Journal of Clinical Pharmacology.

Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents

S. Kapoor, M. Quinlan, S. Dodd, 2022, Clinical and translational science.

Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects

T. Ouatas, Wen-Hu Zhou, K. Umehara, 2019, Cancer Chemotherapy and Pharmacology.

Time Matters - In vitro Cellular Disposition Kinetics Help Rationalizing Cellular Potency Disconnects.

R. Stein, B. Faller, M. Wartmann, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

On the Importance of Metabolic Stability to Achieve High Oral Exposures for Cyclic Peptides

T. Vorherr, M. Schaefer, K. Schroer, 2020, American Journal of Medicinal Chemistry.

Pharmacokinetics of Asciminib When Taken With Imatinib or With Food

M. Quinlan, S. Dodd, P. Aimone, 2021, Clinical pharmacology in drug development.

A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.

P. Manley, J. Schoepfer, S. Moussaoui, 2022, Bioorganic & medicinal chemistry letters.

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes

S. Neelakantham, Andrea J Feller, Swati Dumitras, 2019, European Journal of Clinical Pharmacology.

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

Malcolm Rowland, Shinji Yamazaki, Jun Chen, 2018, Clinical pharmacology and therapeutics.

PBPK models for evaluating membrane transporter mediated DDIs: Current capabilities, case studies, future opportunities and recommendations.

Yuichi Sugiyama, Ming Zheng, Jan Snoeys, 2019, Clinical pharmacology and therapeutics.

Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors

K. Chibale, M. Zollinger, G. Camenisch, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug–drug interaction potential of CYP3A4 substrates

T. Heimbach, K. Umehara, Felix Huth, 2018, Biopharmaceutics & drug disposition.

Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.

R. Woessner, M. Kaul, A. Drollmann, 2022, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Abstract 4477: MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies

F. Colland, Youzhen Wang, Ensar Halilovic, 2019, Experimental and Molecular Therapeutics.

Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes.

G. Kullak-Ublick, M. Arand, G. Camenisch, 2022, Toxicology in vitro : an international journal published in association with BIBRA.

Pyridyl-Ala Modified Cyclic Hexapeptides: In-Vitro and In-Vivo Profiling for Oral Bioavailability

T. Vorherr, M. Schaefer, I. Lewis, 2019, International Journal of Peptide Research and Therapeutics.

A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters

Imad Hanna, Péter Tátrai, B. Poller, 2019, Drug Metabolism and Disposition.